Opendata, web and dolomites

R-LiNK SIGNED

Optimizing response to Li treatment through personalized evaluation of individuals with bipolar I disorder: the R-LiNK initiative

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 R-LiNK project word cloud

Explore the words cloud of the R-LiNK project. It provides you a very rough idea of what is the project "R-LiNK" about.

mood    adherence    stabilizer    guided    disease    suicide    li    tool    effectiveness    stratified    li7    autonomy    whilst    medical    singly    personalization    resonance    predicting    refine    biomarker    exploratory    evaluation    relapse    therapeutics    screening    prevention    majority    bipolar    personalized    patient    criteria    tools    asymptomatic    lli    clinicians    experts    prescribed    bd    signature    prevalent    magnetic    action    sub    expertise    impacts    blood    diagnostics    stratification    data    kits    preliminary    prediction    link    outcomes    edge    life    mechanisms    liresponse    phenotype    quality    industrial    avenues    network    treatment    eligibility    putative    diagnostic    imaging    markers    modal    optimal    powerful    optimize    tolerability    disorder    innovative    technologies    multidisciplinary    safety    molecular    combined    omics    cutting    mental    lithium    bdi    clinical    multinational    biomarkers    responders    brain   

Project "R-LiNK" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://rlink.eu.com/
 Total cost 7˙808˙072 €
 EC max contribution 7˙702˙532 € (99%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2017-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 553˙635.00
2    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 843˙622.00
3    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 798˙093.00
4    ACOBIOM FR (GRABELS) participant 550˙000.00
5    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 485˙360.00
6    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 408˙485.00
7    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) participant 404˙386.00
8    PROVINCIA LOMBARDO VENETA - ORDINEOSPEDALIERO DI SAN GIOVANNI DI DIO- FATEBENEFRATELLI IT (BRESCIA) participant 401˙270.00
9    MONSENSO APS DK (Copenhagen V) participant 381˙250.00
10    INSERM TRANSFERT SA FR (PARIS) participant 357˙375.00
11    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 349˙651.00
12    ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK FR (PARIS) participant 347˙803.00
13    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) participant 299˙235.00
14    KING'S COLLEGE LONDON UK (LONDON) participant 284˙533.00
15    ALCYM FR (SAONE) participant 270˙155.00
16    REGION HOVEDSTADEN DK (HILLEROD) participant 237˙500.00
17    UNIVERSITETET I OSLO NO (OSLO) participant 183˙750.00
18    JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN DE (FRANKFURT AM MAIN) participant 137˙750.00
19    GOETEBORGS UNIVERSITET SE (GOETEBORG) participant 137˙568.00
20    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) participant 137˙347.00
21    CONSORCIO MAR PARC DE SALUT DE BARCELONA ES (BARCELONA) participant 133˙760.00

Map

 Project objective

Bipolar disorder (BD) is a prevalent mental disorder and a leading cause of suicide. Lithium (Li) is the key mood stabilizer for prevention of BD relapse and suicide. Whilst many cases become asymptomatic with Li treatment, the majority show sub-optimal response. Identifying biomarkers for predicting Liresponse would enable personalization of treatment, define criteria for stratification of BD cases and further refine the clinical response phenotype. The objectives of this proposal are to (i) improve outcomes of bipolar I disorder (BDI) cases prescribed Li through the application of stratified approaches; (ii) optimize the early prediction of lLi response using a set of multi-modal biomarkers (“blood omics”, Magnetic Resonance Imaging and Li7-Magnetic Resonance Imaging derived-markers); (iii) develop a multidisciplinary multinational network of experts to undertake this and future projects on personalized diagnostics and therapeutics; and (iv) implement new, powerful technologies to characterize brain Li distribution and the blood molecular signature of Li in responders and non-responders. This cutting edge approach will identify the eligibility criteria for treatment with Li in BD in terms of response, safety and tolerability. The assessment of each putative biomarker (singly and combined) will be guided by preliminary findings already obtained by R-LiNK; our expertise will allow exploratory analyses and innovative modelling of multi-modal data. Likely impacts include improved outcomes and quality of life for BDI cases; development of a screening tool for clinicians; and an evaluation of the cost-effectiveness of this stratified approach. The network will develop new avenues of research on Li mechanisms of action and disease mechanisms; our industrial partnerships will enable development of medical devices to improve treatment adherence and patient’s autonomy, diagnostic kits, and tools based on the molecular signature in treatment responders.

 Publications

year authors and title journal last update
List of publications.
2019 Jan Scott, Diego Hidalgo-Mazzei, Rebecca Strawbridge, Allan Young, Matthieu Resche-Rigon, Bruno Etain, Ole A. Andreassen, Michael Bauer, Djamila Bennabi, Andrew M. Blamire, Fawzi Boumezbeur, Paolo Brambilla, Nadia Cattane, Annamaria Cattaneo, Marie Chupin, Klara Coello, Yann Cointepas, Francesc Colom, David A. Cousins, Caroline Dubertret, Edouard Duchesnay, Adele Ferro, Aitana Garcia-Estela, Jose
Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative
published pages: , ISSN: 2194-7511, DOI: 10.1186/s40345-019-0156-x
International Journal of Bipolar Disorders 7/1 2020-04-24
2018 Jan Scott, Bruno Etain, Frank Bellivier
Can an Integrated Science Approach to Precision Medicine Research Improve Lithium Treatment in Bipolar Disorders?
published pages: , ISSN: 1664-0640, DOI: 10.3389/fpsyt.2018.00360
Frontiers in Psychiatry 9 2020-04-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "R-LINK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "R-LINK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

ARREST-TB (2019)

Accurate, Rapid, Robust and Economical diagnostic technoliogieS for Tuberculosis

Read More  

BRAINTIME (2020)

Molecular atlas of the brain across the human lifespan

Read More  

ESPACE (2020)

Human Cell Atlas of the Pancreas

Read More